Brown Advisory’s 9 Meters Biopharma NMTR Stock Holding History

Brown Advisory’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-722	Closed	-$14K	–	1284
2021 Q4	$14K	Hold	722	–	–	﹤0.01%	1234
2021 Q3	$19K	Buy	+722	New	+$17K	﹤0.01%	1102

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brown Advisory's NMTR Position: Q1 2022 in Review

Brown Advisory sold out of 9 Meters Biopharma (NMTR) in Q1 2022, closing a stake of 722 shares — an estimated $14K sold.

Brown Advisory first reported a position in NMTR in Q3 2021 and held it in 2 quarters. The position peaked at $19K in Q3 2021. 101 funds tracked by Wall St. Rank hold NMTR as of Q1 2022.

Brown Advisory reported no remaining 9 Meters Biopharma position as of Q1 2022 after selling out during the quarter.
Brown Advisory sold 722 9 Meters Biopharma shares in Q1 2022, an estimated $14K.
Brown Advisory first reported a position in 9 Meters Biopharma in Q3 2021 and held it in 2 quarters.
Brown Advisory's 9 Meters Biopharma position peaked at $19K in Q3 2021.
101 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2022.

Based on Brown Advisory's 13F filing for Q1 2022, filed 9 May 2022.